Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study

Table 1 Patient characteristics and prognoses

	Age	Sex	Macroscopic type	Histopathology	Metastasis	Number of courses	Objective tumor response	Prognosis (mo)		Conversion surgery
1	64	M	3	tub2/por	Liver, LNs	7	PR	21.9	Dead
2	59	M	3	tub2/por	LNs	5	PR	50.9	Alive	Yes
3	62	M	2	por	Liver, LNs	6	SD	7.4	Dead
4	65	M	3	por	LNs	5	PR	7.7	Dead
5	67	F	3	tub2/por	LNs	3	non-CR/non-PD	31.3	Alive	Yes
6	66	M	3	por	LNs	4	non-CR/non-PD	12.0	Dead
7	62	M	2	por	Liver, LNs	3	SD	5.4	Dead
8	63	F	2	tub2/por	LNs	4	PR	24.4	Alive	Yes

tub2: Moderately differentiated tubular adenocarcinoma; por: Differentiated adenocarcinoma; LNs: Lymph nodes; PR: Partial response; SD: Stable disease; CR: Complete response.

Table 2 Hematologic and non-hematologic adverse events n (%)

	Any grade	Grade 3	Grade 4
Leukopenia	7 (87.5)	2 (25)	0
Neutropenia	7 (87.5)	4 (50)	2 (25)
Anemia	6 (75)	1 (12.5)	0
Thrombocytopenia	7 (87.5)	0	0
Hyperbilirubinemia	3 (37.5)	0	0
Elevated serum aspartate aminotransferase	6 (75)	0	0
Elevated serum alanine aminotransferase	8 (100)	0	0
Elevated serum creatinine	3 (37.5)	0	0
Fever	4 (50)	0	0
Fatigue	2 (25)	0	0
Alopecia	1 (12.5)	0	0
Skin rash	1 (12.5)	0	0
Anorexia	7 (87.5)	4 (50)	0
Diarrhea	4 (50)	2 (25)	0
Nausea	3 (37.5)	0	0
Vomiting	3 (37.5)	0	0
Constipation	1 (12.5)	0	0
Peripheral neuropathy	1 (12.5)	0	0
Infection	1 (12.5)	1 (12.5)	0

Table 3 Previous reports regarding docetaxel, cisplatin and capecitabine

Ref.	Setting	Capecitabine	Cisplatin	Docetaxel	Interval (d)	Number of patients		Grade 3-4 neutropenia	Febrile neutropenia	RR (95%CI)	PFS (95%CI)	OS (95%CI)	R0 resection	pCR
											(mo)	(mo)
Kang et al[10], 2010	Metastatic or recurrent	1875 mg, days 1-14	60 mg, day 1	60 mg, day 1	21	40		62.5%	10%	68% (53%-83%)	7.6 (6.9-8.4)	14.4 (7.3-21.5)		10.0%
Sym et al[17], 2010	Neoadjuvant	1875 mg, days 1-14	60 mg, day 1	60 mg, day 1	21	49 (36 resected cases)		69%	4%		R0: 54.3 (0-112.9)	R0: not reached	63.0%
											Non-R0: 5.1 (3.6-6.6)	Non-R0: 11.5 (7.3-15.7)
Thuss-Patience et al[12], 2012	Perioperative	1875 mg, days 1-14	60 mg, day 1	75 mg, day1	21	51	Preoperative	76.5%	21.5%				90.2%	13.7%
							Postoperative	62.9%	11.1%
Polyzos et al[16], 2012	Metastatic	2000 mg, days 2-15	60 mg, day 1	60 mg, day 1	21	36		50%	16%	44.4% (28%-60%)	5 (3-6)1	12 (5-24)
Yoon et al[18], 2015	Adjuvant for stage IIIB-IV	1875 mg, days 1-14	60 mg, day 1	60 mg, day 1	21	46		40%	15%		26.9 (7.5-46.4)2	43.9 (29.2-58.7)

¹Time to progression;

²Relapse-free survival. RR: Response rate; PFS: Progression-free survival; OS: Overall survival; pCR: Pathological complete response.